AB-FUBINACA Stats & Data

AB-FUBINACA was initially synthesized by Pfizer in 2009 during research into novel analgesic compounds. The pharmaceutical company never advanced the substance to human clinical trials, and it was subsequently abandoned as a potential medication. The compound first appeared on the recreational drug market in 2012, when Japanese researchers identified it as an active ingredient in synthetic cannabinoid products being sold in that country. It was discovered alongside AB-PINACA, a structurally related compound that had not been previously documented in the scientific literature. AB-FUBINACA subsequently became one of the more prevalent synthetic cannabinoids circulating in recreational drug markets. In August 2018, AB-FUBINACA gained significant public attention following a mass overdose event in New Haven, Connecticut. Beginning on August 15, approximately 70 individuals overdosed in the vicinity of Yale University's campus after consuming adulterated synthetic cannabis products. By the end of that week, over 100 people had required emergency medical transport to local hospitals. Law enforcement subsequently arrested three individuals on charges related to dealing synthetic cannabis products containing AB-FUBINACA.